RITA Medical Systems, Inc is a healthcare technology startup leading the fight against tumors using pioneering radiofrequency ablation technology. The company specializes in creating, producing, and marketing advanced products for patients with both malignant and benign solid tumors. Their exclusive RITA system employs radiofrequency energy to elevate tissue temperature sufficiently to ablate it or induce cell death.
Founded in 1994, RITA Medical Systems focuses on liver cancer and metastatic bone cancer, with plans to expand into treating other tumor types such as those in the lung, breast, uterus, prostate, and kidney. The company has gained regulatory approval in significant markets worldwide, including the United States. Notably, in March 2000, RITA secured the first specific FDA clearance for unresectable liver lesions and, in October 2002, obtained specific FDA clearance for alleviating pain associated with metastatic bone lesions. To date, RITA has globally distributed over 40,000 of its disposable devices.
In their last investment round in January 2003, RITA Medical Systems secured a $9.00M Private Equity investment from BayStar Capital. This investment reflects confidence in the potential of RITA's technological advancements in the fight against tumors.
